Providence Capital Advisors LLC Acquires 324 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Providence Capital Advisors LLC raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.5% during the third quarter, Holdings Channel.com reports. The fund owned 22,091 shares of the medical research company’s stock after buying an additional 324 shares during the period. Providence Capital Advisors LLC’s holdings in IQVIA were worth $5,235,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of IQV. FMR LLC increased its holdings in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of IQVIA in the third quarter worth about $147,683,000. 1832 Asset Management L.P. increased its holdings in shares of IQVIA by 472.3% in the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after purchasing an additional 376,595 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of IQVIA in the second quarter worth about $70,610,000. Finally, Impax Asset Management Group plc increased its holdings in shares of IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after purchasing an additional 264,555 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

Shares of IQV stock opened at $201.44 on Thursday. The business’s fifty day simple moving average is $220.36 and its 200-day simple moving average is $226.57. The company has a market cap of $36.56 billion, a PE ratio of 26.44, a PEG ratio of 2.10 and a beta of 1.51. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on IQV shares. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday. Redburn Atlantic started coverage on IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. JPMorgan Chase & Co. reduced their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft reduced their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Evercore ISI reduced their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.